James C. Yang
Surgery Branch, CCR
National Cancer Institute
United States of America
Dr. Yang graduated from the Massachusetts Institute of Technology with a B.S. in biology. He then completed his M.D. and surgical internship and residency at the University of California, San Diego. In 1984, he came to the Surgery Branch, NCI, as a medical staff fellow. He subsequently became a senior staff fellow, then a senior investigator in 1987. He has been involved in studies of the immune response to tumor-associated antigens and has been a principal investigator of clinical trials in renal cell carcinoma and soft tissue sarcoma.
1. Understanding why human melanomas frequently contain tumor-reactive T cells in their tumor infiltrating lymphocytes (TIL) and why other human tumors appear not to 2. Discovering why human renal cancers respond to immunotherapies very similarly to melanomas, even without containing tumor-reactive TIL 3. Developing the reagents necessary to induce T-cell-mediated rejection of non-melanoma tumors based on principles learned from treating melanoma with T-cell adoptive transfer 4. Clinical Research, 5. Immunology
Melanoma: Why is sentinel lymph node biopsy "standard of care" for melanoma?
Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.